Acorda Therapeutics Inc

NASDAQ:ACOR   3:40:50 PM EDT
0.47
+0.01 (+1.49%)
Earnings Announcements

Acorda Therapeutics Reports Second Quarter 2022 Financial Results

Published: 08/04/2022 20:58 GMT
Acorda Therapeutics Inc (ACOR) - Acorda Therapeutics Reports Second Quarter 2022 Financial Results.
Q2 Non-GAAP Loss per Share $3.15.
Q2 GAAP Loss per Share $2.78.
For Full Year 2022, Acorda Continues to Expect Ampyra Net Revenue to Be $68 - $78 Million.
Revenue is expected to be $30.57 Million
Adjusted EPS is expected to be -$1.56

Next Quarter Revenue Guidance is expected to be $31.01 Million
Next Quarter EPS Guidance is expected to be -$1.11

More details on our Analysts Page.